
|Videos|February 6, 2023
A Look Towards the Future of ESCC
Author(s)Harry H. Yoon, MD, Nabil F. Saba, MD, FACP
Closing out their conversation, Drs Saba and Yoon share their hopes for the future of ESCC, including elucidating the molecular mechanisms behind immune evasion and treatment response to chemotherapy, radiation, and immunotherapy.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
5
































